自律機能障害の患者におけるフェニルプロパノラミンによる強力な圧縮効果

I Biaggioni, J Onrot, C K Stewart

JAMA

|July 10, 1987

まとめ

フェニルプロポナラミン塩化水素は,自律性機能不全および静止性低血圧を有する患者の血圧を効果的に上昇させます. このシンパトミメティック剤は,心拍数を変えることなく,有意な圧縮効果をもたらします.

科学分野:

薬理学薬理学とは
心血管医学心血管医学
神経学神経学とは

背景:

静止性低血圧と自律性不全は,立ち上がったときに血圧が著しく低下することが特徴です.
フェニルプロポナラミン塩化水素は,既知の血管圧縮性を持つシンパトミメティック剤です.

研究の目的:

フェニルプロパノアミンヒドロクロライドの圧縮効果を評価するために,自律機能不全と静止性低血圧に苦しむ患者.
フェニルプロパノアミン水塩化物に対するプレッサー反応の投与量と持続時間を決定する.

主な方法:

自律機能不全と正静性低血圧と診断された14人の患者を対象とした研究.
患者の座っている状態で5分毎に自動装置を用いた継続的な血圧モニタリング.
フェニルプロパノアミンヒドロクロライドを25mgと12.5mgの投与量で口服投与する.

主要な成果:

25mgのフェニルプロパノラミン水塩化物の経口投与は,シストリック血圧 (32 mm Hg),ダイアストリック血圧 (15 mm Hg),および平均血圧 (21 mm Hg) の有意な増加をもたらしました.
圧縮効果は60分以内に観察され,投与後105分まで持続しました.
また,12.5mgの低用量でも,患者のサブセットで血圧が有意に上昇した.
研究中に心拍数の有意な変化は記録されなかった.

結論:

フェニルプロパノアミン水塩化物 (25 mg) は,正静性低血圧の患者に強力な圧力反応を引き起こします.
臨床医は,この薬剤の投与後に著しい高血圧の可能性を認識する必要があります.
この研究は,特定の患者集団における血圧管理におけるフェニルプロパノアミンヒドロクロイドの有効性を強調しています.

さらに関連する動画

06:30

Quantifying Acute Changes in Renal Sympathetic Nerve Activity in Response to Central Nervous System Manipulations in Anesthetized Rats

Published on: September 11, 2018

08:41

Assessment of Vascular Tone Responsiveness using Isolated Mesenteric Arteries with a Focus on Modulation by Perivascular Adipose Tissues

Published on: June 3, 2019

関連する概念動画

01:30

Adrenergic Agonists: Direct-Acting Agents

Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...

01:28

Adrenergic Agonists: Mixed-Action Agents

Mixed-action adrenergic agonists, like ephedrine and pseudoephedrine, directly and indirectly affect adrenergic receptors. These agents stimulate adrenoceptors and indirectly release stored neurotransmitters, amplifying the adrenergic response.
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...

01:30

Adrenergic Agonists: Therapeutic Uses

Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and anaphylaxis:...

01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...

01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...

関連する実験動画